Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?

Mihaela Tevet, Cornel Dragan, Carmen Saguna, Doina Barbu, Anca Roxana Lupu

Open access · greenAbstract readCase Reports

In one paragraph

Article in Maedica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 97% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mihaela TevetDepartment of Hematology, Coltea Clinical Hospital, Bucharest, Romania.

Cornel DraganDepartment of Hematology, Coltea Clinical Hospital, Bucharest, Romania.

Carmen SagunaDepartment of Hematology, Coltea Clinical Hospital, Bucharest, Romania.

Doina BarbuDepartment of Hematology, Coltea Clinical Hospital, Bucharest, Romania.

Anca Roxana LupuDepartment of Hematology, Coltea Clinical Hospital, Bucharest, Romania.

Clinical Emergency Hospital Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractSecondary acute lymphoblastic leukaemia (sALL), defined as acute lymphoblastic leukaemia following another malignancy, irrespective of previous treatment, is a rare disease, and its biological characteristics have not been accurately described. We report the case of a 24-year old patient followed for Hodgkin's lymphoma at our clinic, who develops and is diagnosed, less than a year after obtaining complete remission, as having pro-B acute lymphoblastic leukaemia This case has been a real diagnostic and treatment challenge, as sALL following another haematological malignancy is quite rare.

conclusionIt is necessary to better identify the prognostic factors of haematological malignancies in order to prevent the appearance of sALL.

Indexed as

11q23 mutationalkilating agentsHodgkin's lymphomaimmunophenotypingprognostic factorssecondary acute leukaemia

Identifiers

PMID24790671

PMCPMC3968475

OpenAlexW213993734

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.